Insulet Stock Forecast, Price & News

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Insulet stock.
View analyst ratings for Insulet or view top-rated stocks.

10 Wall Street research analysts have issued twelve-month price objectives for Insulet's stock. Their PODD stock forecasts range from $230.00 to $350.00. On average, they anticipate Insulet's stock price to reach $290.36 in the next year. This suggests a possible upside of 26.0% from the stock's current price.
View analysts' price targets for Insulet or view top-rated stocks among Wall Street analysts.

Insulet's stock was trading at $266.07 at the beginning of the year. Since then, PODD stock has decreased by 13.4% and is now trading at $230.51.
View the best growth stocks for 2022 here.

Insulet is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Insulet.

Insulet Co. (NASDAQ:PODD) issued its quarterly earnings results on Thursday, May, 5th. The medical instruments supplier reported $0.40 earnings per share for the quarter, beating analysts' consensus estimates of $0.23 by $0.17. The medical instruments supplier earned $295.40 million during the quarter, compared to analyst estimates of $287.99 million. Insulet had a trailing twelve-month return on equity of 15.81% and a net margin of 3.91%. The company's revenue was up 17.1% on a year-over-year basis.
View Insulet's earnings history.

Insulet updated its FY 2022 earnings guidance on Monday, May, 23rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.23 billion-$1.27 billion, compared to the consensus revenue estimate of $1.24 billion.

61 employees have rated Insulet CEO Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among Insulet's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Insulet include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), Baxter International (BAX), ResMed (RMD), DexCom (DXCM), IDEXX Laboratories (IDXX), STERIS (STE), Hologic (HOLX), Teleflex (TFX) and Abiomed (ABMD).
View all of PODD's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Square (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD).

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Insulet's stock is owned by many different retail and institutional investors. Top institutional investors include Capital Research Global Investors (9.99%), Vanguard Group Inc. (8.95%), Capital World Investors (6.22%), Clearbridge Investments LLC (2.45%), Primecap Management Co. CA (1.78%) and Echo Street Capital Management LLC (1.16%). Company insiders that own Insulet stock include Bret Christensen, Charles Alpuche, Corinne H Nevinny, David A Lemoine, Eric Benjamin, John A Fallon, Michael P Spears, Sally Crawford, Shacey Petrovic and Wayde D Mcmillan.
View institutional ownership trends for Insulet.

PODD stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Capital Research Global Investors, First Hawaiian Bank, Viking Global Investors LP, Sumitomo Mitsui Trust Holdings Inc., Bank of Nova Scotia, Frontier Capital Management Co. LLC, and Bank of New York Mellon Corp. Company insiders that have sold Insulet company stock in the last two years include Bret Christensen, Charles Alpuche, Eric Benjamin, John A Fallon, Sally Crawford, Shacey Petrovic, and Wayde D Mcmillan.
View insider buying and selling activity for Insulet or view top insider-selling stocks.

PODD stock was acquired by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Clearbridge Investments LLC, Echo Street Capital Management LLC, Ownership Capital B.V., Renaissance Technologies LLC, Blair William & Co. IL, Jag Capital Management LLC, and Vanguard Group Inc..
View insider buying and selling activity for Insulet or or view top insider-buying stocks.

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PODD stock can currently be purchased for approximately $230.51.

Insulet (NASDAQ:PODD) has a market capitalization of $15.98 billion and generates $1.10 billion in revenue each year. The medical instruments supplier earns $16.80 million in net income (profit) each year or $0.629990 on an earnings per share basis.

Insulet employs 2,300 workers across the globe.

Insulet was founded in 2000.

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The official website for Insulet is www.insulet.com. The medical instruments supplier can be reached via phone at (978) 600-7000, via email at [email protected], or via fax at 978-600-0120.